Endocrines
Efficacy and Safety of Remogliflozin in Adults with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis
Por Nikolay Krasimirov Kostadinov, Tzvetelina Totomirova, Zlatko Kirovakov y 1 más.
Contenido en inglés
Resumen
Introduction
Remogliflozin is a sodium–glucose cotransporter-2 inhibitor used for type 2 diabetes mellitus (T2DM), but its overall efficacy and safety remain fragmented. This updated systematic review and meta-analysis evaluated the efficacy and safety of remogliflozin using evidence exclusively from randomized controlled trials (RCTs).
Methods
PubMed; Scopus; and the Cochrane Library were searched from inception to 15 July 2026 for RCTs lasting at least 12 weeks that compared remogliflozin or a remogliflozin-containing regimen with placebo; usual care; or another glucose-lowering treatment in adults with T2DM (PROSPERO: CRD420261462138). Risk ratios (RRs) were calculated using the Mantel–Haenszel method and mean differences (MDs) using the inverse-variance method. Random-effects models with restricted maximum-likelihood estimation and Hartung–Knapp adjustment were applied. Heterogeneity was assessed using I2 and Cochran’s Q test.